Compounds > mefenamic acid

mefenamic acid and propofol

mefenamic acid has been researched along with propofol in 11 studies

Research

Studies (11)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (45.45)	29.6817
2010's	6 (54.55)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chang, TK; Ensom, MH; Kiang, TK	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Wraith, A	1
Kamimura, H; Mano, Y; Usui, T	1
Iwanaga, T; Nagata, O; Nakazawa, T; Omura, K; Sato, T	1
Chen, X; Han, DE; He, J; Yang, S; Yang, Z; Zhang, C; Zhao, D; Zheng, Y	1
Bunjes, H; Kupetz, E	1

Reviews

2 review(s) available for mefenamic acid and propofol

Article	Year
UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacology & therapeutics, 2005, Volume: 106, Issue:1 Topics: Clinical Trials as Topic; Drug Interactions; Enzyme Activation; Enzyme Induction; Glucuronides; Glucuronosyltransferase; Humans; Pharmaceutical Preparations; Pharmacogenetics; Polymorphism, Genetic	2005
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

9 other study(ies) available for mefenamic acid and propofol

Article	Year
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Association of Dental Anaesthetists. Summer Scientific Meeting Stirling, Scotland 8-9 June, 2001. ADA meeting report. SAAD digest, 2001, Volume: 18, Issue:3 Topics: Administration, Oral; Analgesics, Opioid; Anesthesia, Dental; Anesthesia, General; Anesthetics, Intravenous; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Conscious Sedation; Dental Anxiety; Female; Humans; Male; Mefenamic Acid; Molar, Third; Pain, Postoperative; Pediatric Dentistry; Propofol; Referral and Consultation; Therapy, Computer-Assisted; Tooth Extraction; Tramadol	2001
The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug metabolism and disposition: the biological fate of chemicals, 2007, Volume: 35, Issue:11 Topics: Catalysis; Enzyme Inhibitors; Estradiol; Flurbiprofen; Gemfibrozil; Glucuronosyltransferase; Glycosylation; Humans; Hypolipidemic Agents; Isoenzymes; Kinetics; Mefenamic Acid; Microsomes, Liver; Molecular Structure; Morphine; Propofol; Recombinant Proteins	2007
Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor. Drug metabolism and disposition: the biological fate of chemicals, 2007, Volume: 35, Issue:12 Topics: Animals; Baculoviridae; Bilirubin; Biotransformation; Cell Line; Enzyme Inhibitors; Glucuronides; Glucuronosyltransferase; Humans; In Vitro Techniques; Insecta; Intestinal Mucosa; Intestines; Isoenzymes; Kinetics; Mefenamic Acid; Microsomes, Liver; Nitriles; Propofol; Pyridines; Recombinant Proteins; Substrate Specificity; UDP-Glucuronosyltransferase 1A9; Xanthine Dehydrogenase	2007
Identification and characterization of human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of salvianolic acid A. Drug metabolism and pharmacokinetics, 2012, Volume: 27, Issue:6 Topics: Caffeic Acids; Glucuronidase; Glucuronosyltransferase; Humans; Hydrolysis; Intestinal Mucosa; Intestines; Isoenzymes; Kinetics; Lactates; Mefenamic Acid; Microsomes; Microsomes, Liver; Propofol; Statistics as Topic; UDP-Glucuronosyltransferase 1A9	2012
Lipid nanoparticles: drug localization is substance-specific and achievable load depends on the size and physical state of the particles. Journal of controlled release : official journal of the Controlled Release Society, 2014, Sep-10, Volume: 189 Topics: 1-Octanol; Amphotericin B; Chemistry, Pharmaceutical; Curcumin; Dibucaine; Drug Carriers; Emulsifying Agents; Emulsions; Fenofibrate; Mefenamic Acid; Nanoparticles; Particle Size; Poloxamer; Porphyrins; Propofol; Solubility; Triglycerides; Water	2014